Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors

Amaç & Hipotez:OBJECTIVETo date, several methods have been identified for predicting the prognostic subgroups of grade II gliomas; however, these methods have some limitations in predicting survival.

📊

Temel Bulgular & Veri:So, we aimed to determinethe predictive role of Ki-67 labeling index (LI) on survival.METHODSBetween 1995 and 2014, patients with grade II gliomas were retrospectively analyzed.

💡

Sonuç & Katkı:Patients aged ≥40 yearshad a poorer overall survival (OS) than those aged

🔬Tür:Araştırma Makalesi

📍Kapsam:2014 Verileri

⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVETo date, several methods have been identified for predicting the prognostic subgroups of grade II gliomas; however, these methods have some limitations in predicting survival. So, we aimed to determinethe predictive role of Ki-67 labeling index (LI) on survival.METHODSBetween 1995 and 2014, patients with grade II gliomas were retrospectively analyzed. All patients received radiotherapy (RT).RESULTSThis study included 78 patients with median 44 (range, 6–137) months follow-up. Patients aged ≥40 yearshad a poorer overall survival (OS) than those aged

🔖

Bu Makaleye Atıf Yap

AKTAN, M., KANYILMAZ, G., KARAHACIOĞLU, E., ÖNDER, H., BORA, H., KOÇ, M., ERKAL, H. Ş., ERKAL, E. Y. (2022). Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors. Türk Onkoloji Dergisi, Cilt: 33 - Sayı: 2, 48–53. https://ajindex.com/articles/639245

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of lowversus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20(9):2267–76
Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep 2010;10(3):224–31
Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95(5):735–45
Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999;45(4):923–9
Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85(9):704–10
Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79(7):1381–93
Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;77(2):373–80
Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991;12(1):42–9
Morimura T, Kitz K, Stein H, Budka H. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neurooncol 1991;10(1):1–11. 10.Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P. The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours. Acta Neurochir (Wien) 1987;89(3-4):117–21. 11.Zuber P, Hamou MF, de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988;22(2):364–8. 12.Raghavan R, Steart PV, Weller RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol 1990;16(2):123